Mumbai, Oct. 21 -- Zydus Lifesciences (Zydus) today announced that the United States Food and Drug Administration (USFDA) has granted final approval for its Abbreviated New Drug Application (ANDA) for Estradiol and Levonorgestrel Transdermal System, 0.045 mg/0.015 mg per day. (URLD: Climara Pro(R) Transdermal System 0.045 mg/0.015 mg per day).

Published by HT Digital Content Services with permission from Capital Market....